Factors Affecting Mortality in Covid-19 Disease

NCT06043115 | Completed

• 1 other identifier: Akdeniz University Faculty
• Study Type: observational
• Target: 619
• Locations: 1 country
• Sites: 1

Brief Summary

The coronavirus disease-19 (COVID-19), defined by the reporting of pneumonia cases of unknown etiology at the end of 2019 in Wuhan, China, has spread worldwide, causing millions of deaths. Despite the fact that more than two years have passed since the struggle against the disease it continues to be an important public health problem.The increasing number of critically ill patients with this pandemic caused a great demand for intensive care units (ICU), and ICU capacity and staff had to be rapidly expanded in many countries. Similarly, in various periods of the pandemic in Turkey, the capacity of many ICUs had to be increased. The rates of admission to the ICU and death rates differed greatly from center to center due to various factors such as ICU bed capacity and the duration of access to the ICU, patient characteristics, and differences in the treatments applied. Determining the factors that may be associated with mortality is important in terms of improving the ICU follow-up of patients with COVID-19 and guiding their treatment.There is limited information about the characteristics and mortality of Turkish patients with COVID-19 in the ICU. The aim of this study is to determine the demographic, clinical and laboratory characteristics and the factors affecting ICU mortality in COVID-19 patients followed in Akdeniz University Medical Faculty Hospital since the beginning of the pandemic.

Conditions

COVID-19 Pneumonia; Mortality

Outcome Measures

Primary Outcomes (1)

• factors affecting mortality in COVID-19

  clinical and laboratory characteristics of COVID-19 patients in mortality of ICU.

  11 March 2020 -31 March 2022

Secondary Outcomes (1)

• difference between the pandemic waves

  11 March 2020-31 March 2022

Study Arms (2)

covid-19 survival cohort

consists of surviving patients

Other: covid-19 survival cohort

covid-19 mortality cohort

consists of deceased patients

Other: covid-19 mortality cohort

Interventions

covid-19 survival cohort OTHER

consists of surviving patients

covid-19 survival cohort

covid-19 mortality cohort OTHER

consists of deceased patients

covid-19 mortality cohort

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients aged ≥18 years with a confrmed diagnosis of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection by a positive real-time reverse-transcription polymerase chain reaction test (RT-PCR) on a nasopharyngeal swab or endotracheal aspirate were included in the present study.

You may qualify if:

• Patients aged ≥18 years with a confrmed diagnosis of the severe acute respiratory syndrome coronavirus-2 infection by a positive real-time reverse-transcription polymerase chain reaction test

You may not qualify if:

• Patients whose SARS-CoV-2 RT-PCR test was negative
• Chest computed tomography findings or symptoms were not compatible with COVID-19

Sponsors & Collaborators

• Melike Cengiz: lead

Study Sites (1)

Akdeniz University School of Medicine, Department of Anesthesiology and Intensive Care, Turkey

Antalya, Turkey (Türkiye)

Location

Study Officials

• Burcu Ozer, MD

  Akdeniz University School of Medicine, Department of Anesthesiology and Reanimation, Turkey

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: MD,Professor Doctor

Study Record Dates

• First Submitted: September 9, 2023
• First Posted: September 21, 2023
• Study Start: May 11, 2022
• Primary Completion: November 30, 2022
• Study Completion: December 15, 2022
• Last Updated: September 21, 2023

Record last verified: 2023-09

Locations

TU (1)